



## New strategies for treatment of *Candida* vaginal infections

Walter Magliani, Stefania Conti, Antonella Salati, Simona Arseni, Raffaele Frazzi, Lara Ravanetti & Luciano Polonelli

Dipartimento di Patologia e Medicina di Laboratorio, Sezione di Microbiologia, Università degli Studi di Parma, Italy

### Summary

New strategies for treatment of vaginal candidiasis have been recently exploited, due to widespread occurrence of this disease, in particular as recurrent infections, limitations of safe and efficacious antifungals as well as the lack of reliable preventative approaches. In this review new chemotherapeutic and immunotherapeutic strategies, based on the improved understanding of the immunopathogenesis of this prevalent human infection, will be discussed. The role of killer antibodies (or their molecular derivatives), i.e. antibodies that show antibiotic activity bearing the internal image of a yeast killer toxin (KT), characterized by a wide spectrum of microbicidal activity, and of the specific cell wall KT receptor as putative new therapeutic agents and preventative or therapeutic vaccines, respectively, will be particularly outlined.

### Key words

Vaginal candidiasis, Anticandidal chemotherapy, Anticandidal immunotherapy, Anticandidal vaccines, Killer antibodies

## Nuevas estrategias en el tratamiento de las infecciones vaginales por *Candida*

### Resumen

Se están empleando nuevas estrategias para el tratamiento de la candidiasis vaginal, debido a la amplia ocurrencia de esta enfermedad, particularmente como infecciones recurrentes, la oferta limitada de antifúngicos seguros y eficaces, así como la falta de una profilaxis fiable. En esta revisión se discuten las nuevas estrategias quimioterapéuticas e inmunoterapéuticas basadas en la cada vez mejor comprensión de la inmunopatogénesis de esta prevalente infección humana. Destacamos especialmente el papel de los anticuerpos agresores (o sus derivados moleculares), p.ej. anticuerpos con actividad antibiótica por contener la imagen interna de una toxina "asesina" que se caracteriza por un amplio espectro de actividad microbicida, y del receptor de la pared celular específico para la toxina "asesina", como posibles nuevos agentes terapéuticos o vacunas preventivas o terapéuticas, respectivamente.

### Palabras clave

Candidiasis vaginal, Quimioterapia anticandidiásica, Inmunoterapia anticandidiásica, Vacunas anticandidiásicas, Anticuerpos agresores

Despite the availability of several potent antifungal agents and new insights into the host-fungus interplay, *Candida* vaginitis remains a common and frequently distressing infection affecting millions of women worldwide. On the basis of the clinical symptoms and the predicted response to antifungal therapy, in 1997 a new classification of *Candida* vaginitis, into uncomplicated (vulvovaginal candidiasis - VVC -) and complicated (severe or recurrent VVC, non-*albicans* *Candida* species or abnormal host) disease was recommended [1].

VVC frequently affects women of child-bearing age and postmenopausal women who have underlying risk factors, such as hormone replacement therapy and immunosuppression caused by medication or disease [1-4]. Diabetes mellitus, particularly type 1, increases the rate of vaginal colonization and infection with *Candida* species [5,6]. Fewer than 5% of women with a primary episode subsequently experience frustrating recurrent VVC (RVVC), i.e. they develop at least three-four specific episodes within one year, in part without any known predisposing factors [7,8].

*C. albicans* is still recognized as the most frequent aetiological agent of VVC and RVVC, with a highly significant relationship between high estrogen levels and the occurrence of infection, probably due to the production of glycogen, an attractive substrate for the yeast, by oestrogen stimulated epithelial cells [9]. Vaginal epithelial cells from mice, nonhuman primates and healthy women inhibit the growth of *C. albicans* *in vitro*, which may represent an innate host resistance mechanism against *Candida*. Women affected by RVVC have reduced epithelial cell anti-*Candida* activity that may contribute to the disease [10-12].

### Dirección para correspondencia:

Prof. Luciano Polonelli  
Dipartimento di Patologia e Medicina di Laboratorio  
Sezione di Microbiologia  
Università degli Studi di Parma  
Viale Gramsci, 14  
43100 Parma, Italy  
Tel.: +39 0521 988877  
Fax: +39 0521 993620  
E-mail: magliwal@unipr.it

Recent studies clearly show that an increasing percentage of vaginal infections have to be ascribed to non-*albicans* species, such as *C. glabrata* and more rarely *C. krusei*, innately less susceptible to most antifungal agents [13,14]. The increasing use of “over the counter” (OTC) antifungal treatments, as well as widespread prescription of systemic oral azoles, could have resulted in spread of azole-resistant *C. albicans*, and even more likely of non-*albicans* *Candida* species with intrinsic azole resistance. Even if data on correlation between OTC exposure and colonization of drug-resistant *Candida* in vaginal microbiota are conflicting, self-medication with OTC without establishing a proper diagnosis could expose women to unnecessary antifungal treatments and to the risk of missing other causes or concurrent infections, contributing to a selection pressure in favor of more resistant species [15-17].

Innate as well as acquired humoral and cell-mediated immune (CMI) responses are involved in the defense against *Candida* infection. In particular, T-cell-dependent CMI is considered to play a key role for prevention of mucocutaneous infections [18,19]. Furthermore, cytokines produced by monocytes during the innate response may modify T cell-mediated immune response and different *Candida* species can induce differential production of immunoregulatory cytokines during infection [20,21].

The role of antibodies in this scenario is still controversial, probably because the antigenic complexity of *Candida* is responsible for the production of a plethora of different antibodies, including protective antibodies directed against a limited number of epitopes that are probably not produced at sufficient levels during natural infections. Protection against *Candida* infection probably requires a deep interaction of all the above mentioned host factors [22]. To date, observations coming from studies in women with RVVC, in HIV-infected women, and in animal models of experimental vaginitis, demonstrate that local immunity is more important than that in the systemic circulation for host defense against vaginitis, suggesting an immunological independence or compartmentalization of the vaginal mucosa [23-28]. Gamma/delta T cells have been suggested to play an immunoregulatory role in *Candida* vaginitis [29].

T helper (Th) 1, such as gamma interferon (IFN- $\gamma$ ) and interleukin-12 (IL-12), and Th 2 cytokines, such as IL-10, are produced at the vaginal level, with little to no modulation in response to infection [24]. Vaginal epithelial cells produce constitutively chemokines and proinflammatory cytokines, such as IL-1 $\alpha$ , tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) and others, that, if produced *in vivo*, could be responsible for the inflammatory condition (edema and erythema) associated to VVC [30]. In experimental murine infections, transforming growth factor  $\beta$ 1 (TGF- $\beta$ 1) was found in the vaginal fluids at high levels, and it could be responsible for a downregulatory or tolerance role [28]. Local production of chemokines, such as MCP-1, plays some role in reducing the fungal burden during experimental vaginal candidiasis in a manner independent of cellular chemotactic activity [31]. Recent evidences indicate an important role for dendritic cells (DC), particularly abundant at the skin and mucosal surfaces, in discriminating between the two forms of *C. albicans* (filamentous and budding yeast) in terms of elicited immune responses. By producing IL-4 and IL-12 in response to the virulent and nonvirulent forms of the fungus, DC have been demonstrated to be capable of Th priming, initiating T cell immunity [32].

Finally, *C. albicans* in some situations can act as a potent allergen and it has been suggested that local hypersensitivity to the yeast can be a factor in the prolongation

of the disease [33]. RVVC would be correlated to a still undefined local immune deficiency or dysfunction [34].

The complexity of the immunopathology, the wide spectrum of clinical VVC and the pharmacotherapeutic failures in the treatment of *Candida* vaginitis require the implementation of all known measures to fight the pathogen and call for new therapeutic tools and strategies. Two areas have been recently deeply investigated and will be outlined: antimycotic chemotherapy and immunotherapy.

### New chemotherapeutic strategies for treatment of *Candida* vaginal infections

Despite the availability of antifungals for oral and intra-vaginal treatment of VVC, unmet needs still exist for new therapeutic agents or schedules. As outlined by Sobel [35], perhaps the most important advance in this field in the last decade has been the recognition that not all forms of *Candida* vaginitis are equal and that their treatment requires individualization. Clinical evaluation of recurrent episodes as well as microbiological approaches to identify the aetiologic agent are essential to address the optimal therapeutic approach.

Most of the women with uncomplicated *Candida* vaginitis respond well to short-course therapy with fluconazole, the oral route being the preferred route of administration [36-39]. No differences have been observed between the relative effectiveness of oral and intra-vaginal antifungal treatment of *Candida* vaginitis; duration of therapy seems to be the most critical factor [40]. Although antifungal therapy is highly effective for individual attacks, persistence of vaginal colonization and recurrences after therapy are quite common, at least in part due to the fungistatic activity of azoles and caused by persistent yeast in the vagina, rather than by re-infections [41]. Women with recurrences of mild or moderate severity respond well to a single dose of fluconazole in the short term [42]; in contrast, women with complicated *Candida* vaginitis could require antimycotic therapies of longer duration to achieve clinical cure and mycologic eradication and to break the pattern of recurrence. After the acute episode has been treated, subsequent prophylaxis (maintenance therapy) could be important to prevent future frequent relapses, and long-term therapy may be warranted because of recurrences once prophylaxis is discontinued [43-45]. Treatment with sequential doses of fluconazole enhances clinical cure and mycologic eradication rates in patients infected with *C. albicans* [42].

Little evidence exists that antimicrobial resistance could be involved in RVVC, but the spread of non-*albicans* *Candida* species with intrinsic azole resistance may be an emerging concern, adversely influencing outcome of therapy [46]. Combined topical flucytosine and amphotericin B [47], terconazole cream [48] and others have been proposed. Maintenance therapy with topical boric acid has been experienced, but its efficacy in the cure of vaginitis and in the prevention of relapses ends with the suspension of the therapy [49].

There is a need of new antifungal drugs with greater potency and a broader spectrum of activity. Some of them, such as sordarins and caspofungin, characterized by mechanisms of action escaping consolidate acquired resistance, are promising and under study [50-53]. Problems inherent to antifungal chemotherapy and the attempt to preserve effective drugs by sparing their use have prompted recent interest and investigations of non-drug alternative or integrative strategies for candidiasis, such as immunotherapy [54-57].

## New immunotherapeutic strategies for treatment of *Candida* vaginal infections

As outlined before, better understanding of the immunopathogenesis of VVC and RVVC and identification and characterization of immunodominant candidal antigens would be crucial to address optimal immunotherapeutic approaches to human candidiasis. Preventive or therapeutic vaccination and antibody-mediated immunotherapy have been recently proposed as new potential approaches.

Members of the secretory aspartyl proteinase (Sap) gene family, in particular Sap2 [58-60], a 65kDa manno-protein (MP65) [61], surface mannan [62], a mannoprotein extract (MP) [63], and other constituents of *Candida* cell, have been proposed as immunodominant candidal antigens able to stimulate a potentially protective immune response against either systemic and/or mucosal candidiasis, and have been considered as potential vaccine candidates. Natural and monoclonal antibodies generated against some of those antigens proved to be protective when given before infection and therapeutic when given after infection [62].

Intravaginal and intranasal (i.n.) immunizations with MP or secreted Sap of *C. albicans*, with an appropriate adjuvant, have been demonstrated to be equally effective in inducing vaginal antibodies and in conferring protection against vaginal candidiasis [63].

Protection from systemic fungus challenges has been demonstrated by i.n. delivery of a vaccine consisting of whole inactivated *Candida* cells and a cholera-toxin-like mucosal adjuvant [64] as well as by injection of DC pulsed with *Candida* yeasts or yeast RNA, even in hematopoietic transplantation [65].

Over the past years, a new idiotypic (Id) vaccination and anti-Id therapy approaches against systemic and mucosal *Candida* infections have been described, on the basis of the theory of the Id network [66] and the yeast killer phenomenon [67]. A murine monoclonal antibody (mAb KT4) that neutralized the wide-spectrum antimicrobial activity of a killer toxin (KT) from a selected strain of the yeast *Pichia anomala* (PaKT) [68] was used as a parenteral or mucosal Id vaccine in animal (rabbit, rat, mouse) experimental models, eliciting the production of protective serum or secretory anti-Id antibodies. These antibodies carried the internal image of PaKT, in that they were able to functionally mimic it, and were designated as killer antibodies (KABs) [69-71]. Mab KT4-affinity chromatography-purified serum or secretory KABs exerted a direct significant *in vitro* killer activity against PaKT-susceptible *C. albicans* cells by interacting with a specific not yet identified putative cell wall KT receptor (KTR), mainly expressed in budding cells and germe tubes, and were able to confer passive immunoprotection to unvaccinated experimentally infected animals. Particularly, intravaginal immunization with mAb KT4 resulted in effective protection in a well established rat model of candidal vaginitis [72].

The functional equivalence of KABs with PaKT suggested a similar homology between the Id of mAb KT4 and KTR. Such an hypothesis was demonstrated in that KABs and PaKT competed for the binding site of mAb KT4, intravaginal or intragastric inoculations of PaKT-sensitive *C. albicans* cells were able to recall mucosal KABs production in rats primarily immunized intravaginally with mAb KT4 and to elicit by themselves antibodies that functionally mimicked PaKT. More interestingly, the latter observation was confirmed also in women experiencing RVVC, who had obviously never

been exposed to the Id vaccine; from their vaginal fluid natural anti-KTR KABs functionally similar to those previously described were significantly revealed and purified by affinity-chromatography. These purified anti-KTR human natural KABs proved to confer immunoprotection by passive transfer to rats in the experimental model of vaginal candidiasis [73]. These data demonstrate that KABs should be part of the Ab repertoire elicited by experimental and natural *Candida* infections, even though their clinical role in human disease remains to be elucidated. As described in experimental infections with *C. neoformans* [74], natural KABs might be produced at non-protective levels, due to not constitutive expression of KTR on the *Candida* cell wall, and their activity might be interfered or even inhibited by the plethora of antibodies directed against other surface strongly antigenic constituents of the fungus cell wall. Once characterized, purified KTR and mAb KT4 idiotype could deserve great consideration as putative new anti-*Candida* vaccines.

A rat monoclonal KAB (mKAb) [75] and a mouse recombinant KAB in the single-chain format (rKAb) [76] have been produced, by hybridoma and phage display technologies from the spleen lymphocytes of animals immunized by idiotypic vaccination with mAb KT4. Both the molecules were able to kill *C. albicans in vitro*, bind to specific KTR on the yeast cells, and exert a strong therapeutic effect in the experimental model of rat vaginal candidiasis.

Cloning of the rKAb gene in a suitable vector in the human commensal *Streptococcus gordonii* allowed its expression as a secreted or surface-displayed molecule. The engineered streptococcal clones demonstrated to be highly efficacious in killing *C. albicans in vitro* and in significantly accelerating the clearance of high fungus burdens in the rat model of *Candida* vaginitis, persistently colonizing the vaginal mucosa. Stable colonization with the secreting strain, in particular, was as therapeutic as a full course of fluconazole [77].

On the basis of the previous observations and sequencing of the rKAb gene, two different experimental immunotherapeutic developments are under study.

Recent studies have characterized KTR as a component of the glucan fraction of the inner cell wall of *C. albicans*. Immunization of mice with fungal cells deprived of cell-surface constituents, such as mannoproteins, thus exposing the underlying  $\beta$ -glucan-rich components, resulted in a significant protection against systemic, lethal infections by *C. albicans*, at least in part mediated by antibodies, with anti- $\beta$ -glucan IgM playing a relevant role [78]. These results and those reported by others, previously mentioned, stimulate to further study the preventative or therapeutic use of different putative vaccine candidates against vaginal candidiasis.

On the other side, a decapeptide synthesized and optimized from the sequence of the rKAb gene was demonstrated to maintain the strong *in vitro* candidacidal activity of rKAb and, when used to treat experimental vaginal and systemic candidiasis, it exerted a significant therapeutic activity, similar to that of fluconazole, being fully active also against a fluconazole-resistant strain of *C. albicans* (manuscript in preparation). Thus, synthetic killer mimotopes could represent conceptually new candidacidal therapeutic agents.

A further major interest of these approaches could rely on their potential wide antimicrobial spectrum. As the original KT, its anti-Id polyclonal, monoclonal and recombinant derivatives have been demonstrated to be microbicidal against a wide spectrum of epidemiologically important prokaryotic and eukaryotic pathogens

such as azole-resistant *Candida*, *Pneumocystis carinii*, *Aspergillus fumigatus*, *Cryptococcus neoformans*, *Mycobacterium tuberculosis*, methicillin and vancomycin resistant cocci, and others [79-83].

The existence of a putative transphyletic KTR and its use as a multivalent vaccine could open new perspectives in the investigation of its ability to protect against several mucosal and systemic diseases caused by infectious PaKT-sensitive microorganisms presenting KTR on their surface and of the wide-spectrum therapeutic activity of recombinant and synthetic derivatives of KAbs, that could represent conceptually new antimicrobial agents also deliverable at the mucosal sites by engineered commensal bacteria.

These approaches could be of wider potential in that specific toxin receptors of microbial pathogens and the Id of antibodies specifically neutralizing the biological activity of those toxins could be used to produce micro-

bial antibodies and their molecular derivatives representing the internal images of antimicrobial toxins, thus mimicking the evolution of the biological competition occurring among microorganisms in natural habitats [84].

Finally, need still exists for further molecular, biochemical and immunological studies to validate and strengthen these experimental evidences and to determine the immune correlates at the basis of disease, protection and successful therapy. The concerted use of drugs, antibodies or their derivatives and cytokines and the development of reliable and safe vaccines will probably be in the next future the most potentially powerful approaches for the treatment or the prevention of mucosal as well as systemic candidal infections.

*The authors' studies cited in this review have been supported by Ministero della Sanità, Istituto Superiore di Sanità, Programma Nazionale di Ricerca sull'AIDS - Progetto "Infezioni opportunistiche e TBC derivanti dall'AIDS".*

## References

1. Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic and therapeutic considerations. *Am J Obstet Gynecol* 1998; 178: 203-211.
2. Foxman B, Barlow R, d'Arcy H, et al. *Candida* vaginitis: estimated incidence and associated costs. *Sex Transm Dis* 2000; 27: 230-235.
3. Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case control study among university students. *Epidemiol* 1998; 7: 182-187.
4. Reed BD. Risk factors for *Candida* vulvovaginitis. *Obstet Gynecol Surv* 1992; 47: 551-560.
5. de Leon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal *Candida* colonization in women with type 1 and type 2 diabetes. *BMJ Infect Dis* 2002; 2: 1.
6. Goswami R., Dadhwal V, Tejaswi S, et al. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. *J Infect* 2000; 41: 162-166.
7. Hurley R. Recurrent *Candida* infection. *Clin Obstet Gynecol* 1981; 8: 209-213.
8. Sobel JD. Pathogenesis and epidemiology of vulvovaginal candidiasis. *Ann NY Acad Sci* 1988; 544: 547-557.
9. Dennerstein GJ, Ellis DH. Oestrogen, glyco-gen and vaginal candidiasis. *Aust N Z J Obstet Gynaecol* 2001; 41: 326-328.
10. Barousse MM, Steele C, Dunlap K, et al. Growth inhibition of *Candida albicans* by human vaginal epithelial cells. *J Infect Dis* 2001; 184: 1489-1493.
11. Steele C, Ozenci H, Luo W, et al. Growth inhibition of *Candida albicans* by vaginal cells from naive mice. *Med Mycol* 1999; 37: 251-259.
12. Steele C, Leigh J, Swoboda R, Fidel PL Jr. Growth inhibition of *Candida* by human oral epithelial cells. *J Infect Dis* 2000; 182: 1479-1485.
13. Abu-Elteen KH. Increased incidence of vulvovaginal candidiasis caused by *Candida glabrata* in Jordan. *Jpn J Infect Dis* 2001; 54: 103-107.
14. Sobel JD. Vulvovaginitis due to *Candida glabrata*: an emerging problem. *Mycoses* 1998; 41 (Suppl 2): 18-22.
15. Ferris DG, Nyirjesy P, Sobel JD, et al. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. *Obstet Gynecol* 2002; 99: 419-425.
16. Mathema B, Cross E, Dun E, et al. Prevalence of vaginal colonization by drug-resistant *Candida* species in college-age women with previous exposure to over-the-counter azole antifungals. *Clin Infect Dis* 2001; 33: E23-27.
17. Walker PP, Reynolds MT, Ashbee HR, et al. Vaginal yeasts in the era of "over the counter" antifungals. *Sex Transm Infect* 2000; 76: 437-438.
18. Fidel PL Jr. Vaginal candidiasis: review and role of local mucosal immunity. *AIDS Pat Care Sex Transm Dis* 1998; 12: 359-366.
19. Fukazawa Y, Cassone A, Bistoni F, et al. Mechanisms of cell-mediated immunity in fungal infections: a review. *J Med Vet Mycol* 1994; 32: 123-131.
20. Brieland J, Essig D, Jackson C, et al. Comparison of pathogenesis and host immune responses to *Candida glabrata* and *Candida albicans* in systemically infected immunocompetent mice. *Infect Immun* 2001; 69: 5046-5055.
21. Xiong J, Kang K, Liu L, et al. *Candida albicans* and *Candida krusei* differentially induce human blood mononuclear cell interleukin-12 and gamma interferon production. *Infect Immun* 2000; 68: 2464-2469.
22. Casadevall A, Cassone A., Bistoni F, et al. Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute? *Med Mycol* 1998; 36(S1): 95-105.
23. De Bernardis F, Santoni G, Bocconera M, et al. Local anticandidal immune responses in a rat model of vaginal infection by and protection against *Candida albicans*. *Infect Immun* 2000; 68: 3297-3304.
24. Fidel PL Jr, Ginsburg KA, Cutright JL, et al. Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: evidence for vaginal Th1-type responses following intravaginal challenge with *Candida* antigen. *J Infect Dis* 1997; 176: 728-739.
25. Fidel PL Jr, Luo W, Chabain J, et al. Use of cellular depletion analysis to examine circulation of immune effector function between the vagina and the periphery. *Infect Immun* 1997; 65: 3939-3943.
26. Fidel PL Jr, Luo W, Steele C, et al. Analysis of vaginal cell populations during experimental vaginal candidiasis. *Infect Immun* 1999; 67: 3135-3140.
27. Fidel PL Jr, Wolf NA, Kukuruga MA. T lymphocytes in the murine vaginal mucosa are phenotypically distinct from those in the periphery. *Infect Immun* 1996; 64: 3793-3799.
28. Taylor BN, Saavedra M, Fidel PL Jr. Local Th1/Th2 cytokine production during experimental vaginal candidiasis: potential of transforming growth factor-beta. *Med Mycol* 2000; 38: 419-431.
29. Wormley FL Jr, Steele C, Wozniak K, et al. Resistance of T-cell receptor delta-chain-deficient mice to experimental *Candida albicans* vaginitis. *Infect Immun* 2001; 69: 7162-7164.
30. Steele C, Fidel PL Jr. Cytokine and chemokine production by human oral and vaginal epithelial cells in response to *Candida albicans*. *Infect Immun* 2002; 70: 577-583.
31. Saavedra M, Taylor B, Lukacs N, Fidel PL Jr. Local production of chemokines during experimental vaginal candidiasis. *Infect Immun* 1999; 67: 5820-5826.
32. Fè d'Ostiani C, Del Sero G, Bacci A, et al. Dendritic cells discriminate between yeasts and hyphae of the fungus *Candida albicans*: implications for initiation of T helper cell immunity in vitro and in vivo. *J Exp Med* 2000; 191: 1661-1674.
33. Moraes PS, deLima Goiaba S, Taketomi EA. *Candida albicans* allergen immunotherapy in recurrent vaginal candidiasis. *J Investig Allergol Clin Immunol* 2000; 10: 305-309.
34. Fidel PL Jr, Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. *Clin Microbiol Rev* 1996; 9: 335-348.
35. Sobel JD. Limitations of antifungal agents in the treatment of *Candida* vaginitis: future challenges. *Drug Resist Updat* 1999; 2: 148-152.
36. Sobel JD, Brooker D, Stein GE, et al. Single oral dose fluconazole compared with conventional topical therapy of *Candida* vaginitis. *Am J Obstet Gynecol* 1995; 172: 1263-1268.
37. Edelman DA, Grant S. One-day therapy for vaginal candidiasis. *J Reprod Med* 1999; 44: 543-547.
38. Kaplan B, Rabinerson D, Gibor Y. Single-dose systemic oral fluconazole for the treatment of vaginal candidiasis. *Int J Gynecol Obstet* 1997; 57: 281-286.
39. Mikamo H, Kawazoe K, Sato Y, et al. Comparative study on the effectiveness of antifungal agents in different regimens

- against vaginal candidiasis. Chemotherapy 1998; 44: 364-368.
40. Watson MC, Grimshaw JM, Bond CM, *et al.* Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review. Br J Obstet Gynecol 2002; 109: 85-95.
  41. Vazquez JA, Sobel JD, Demitriou R, *et al.* Karyotyping of *Candida albicans* isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. J Infect Dis 1994; 170: 1566-1569.
  42. Sobel JD, Kapernick PS, Zervos M, *et al.* Treatment of complicated *Candida* vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001; 185: 363-369.
  43. Nwokolo NC, Boag FC. Chronic vaginal candidiasis. Management in the postmenopausal patient. Drugs Aging 2000; 16: 335-339.
  44. Nyirjesy P. Chronic vulvovaginal candidiasis. Am Fam Physician 2001; 63: 697-702.
  45. Ringdahl EN. Treatment of recurrent vulvovaginal candidiasis. Am Fam Physician 2000; 61: 3306-3312.
  46. Sobel JD. Antimicrobial resistance in vulvovaginitis. Curr Infect Dis Rep 2001; 3: 546-549.
  47. White DJ, Habib AR, Vanthuyne A, *et al.* Combined topical flucytosine and amphotericin B for refractory vaginal *Candida glabrata* infections. Sex Transm Infect 2001; 77: 212-213.
  48. Sood G, Nyirjesy P, Weitz MV, Chatwani A. Terconazole cream for non-*Candida albicans* fungal vaginitis: results of a retrospective analysis. Infect Dis Obstet Gynecol 2000; 8: 240-243.
  49. Guaschino S, De Seta F, Sartore A, *et al.* Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2001; 184: 598-602.
  50. Kaneko S, Uchida T, Shibuya S, *et al.* Synthesis of sordarin analogues as potent antifungal agents against *Candida albicans*. Bioorg Med Chem Lett 2002; 12: 803-806.
  51. Justice MC, Hsu M-J, Tse B, *et al.* Elongation factor 2 as a novel target for selective inhibition of fungal protein synthesis. J Biol Chem 1998; 273: 3148-3151.
  52. Martinez A, Ferre S, Santos I, *et al.* Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats. Antimicrob Agents Chemother 2001; 45: 3304-3309.
  53. Onishi J, Meinz M, Thompson J, *et al.* Discovery of novel antifungal (1,3)- $\beta$ -D-glucan synthase inhibitors. Antimicrob Agents Chemother 2000; 44: 368-377.
  54. Magliani W, Conti S, Arseni S, *et al.* Killer anti-idiotypes in the control of fungal infections. Curr Opin Invest Drugs 2001; 2: 477-479.
  55. Magliani W, Conti S, Cassone A, *et al.* New immunotherapeutic strategies to control vaginal candidiasis. Trends Mol Med 2002; 8: 121-126.
  56. Polonelli L, Cassone A. Novel strategies for treating candidiasis. Curr Opin Infect Dis 1999; 12: 61-66.
  57. Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 1998; 26: 1266-1269.
  58. Cassone A, Boccanera M, Adriani D, *et al.* Rats clearing a vaginal infection by *Candida albicans* acquire specific, antibody-mediated resistance to vaginal reinfection. Infect Immun 1995; 65: 2619-2625.
  59. De Bernardis F, Boccanera M, Adriani D, *et al.* Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of *Candida albicans* vaginitis in rats. Infect Immun 1997; 66: 3399-3405.
  60. De Bernardis F, Sullivan PA, Cassone A. Aspartyl proteinases of *Candida albicans* and their role in pathogenicity. Med Mycol 2001; 39: 303-313.
  61. Gomez MJ, Torosantucci A, Arancia S, *et al.* Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of anti-*Candida* cell-mediated immune responses in humans. Infect Immun 1996; 64: 2577-2584.
  62. Han Y, Morrison RP, Cutler JE. A vaccine and monoclonal antibodies that enhance mouse resistance to *Candida albicans* vaginal infection. Infect Immun 1998; 66: 5771-5776.
  63. De Bernardis F, Boccanera M, Adriani D, *et al.* Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect Immun 2002; 70: 2725-2729.
  64. Cardenas-Freytag L, Cheng E, Mayeux P, *et al.* Effectiveness of a vaccine composed of heat-killed *Candida albicans* and a novel mucosal adjuvant LT(R192G) against systemic candidiasis. Infect Immun 1999; 67: 826-833.
  65. Bacci A, Montagnoli C, Perruccio K, *et al.* Dendritic cells pulsed with fungal RNA induce protective immunity to *Candida albicans* in hematopoietic transplantation. J Immunol 2002; 168: 2904-2913.
  66. Jerne NK. Towards a network theory of the immune system. Ann Immunol (Institut Pasteur) 1974; 125C: 373-389.
  67. Magliani W, Conti S, Gerloni M, *et al.* Yeast Killer Systems. Clin Microbiol Rev 1997; 10: 369-400.
  68. Polonelli L, Morace G. Production and characterization of yeast killer toxin monoclonal antibodies. J Clin Microbiol 1987; 25: 460-462.
  69. Polonelli L, Fanti F, Conti S, *et al.* Detection by immunofluorescent anti-idiotypic antibodies of yeast killer toxin cell wall receptors of *Candida albicans*. J Immunol Methods 1990; 132: 205-209.
  70. Polonelli L, Lorenzini R, De Bernardis F, *et al.* Idiotype vaccination: Immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity. Scand J Immunol 1993; 37: 105-110.
  71. Polonelli L, De Bernardis F, Conti S, *et al.* Idiotype intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol 1994; 152: 3175-3182.
  72. De Bernardis F, Lorenzini R, Cassone A. A rat model of *Candida* vaginal infection. In: Zak O, Sande MA (Eds.) Handbook of animal models of infection. New York, Academic Press, 1999: 735-740.
  73. Polonelli L, De Bernardis F, Conti S, *et al.* Human natural yeast killer toxin-like candidacidal antibodies. J Immunol 1996; 156: 1880-1885.
  74. Casadevall A. Antibody immunity and invasive fungal infections. Infect Immun 1995; 63: 4211-4218.
  75. Polonelli L, Seguy N, Conti S, *et al.* Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies. Clin Diagn Lab Immunol 1997; 4: 142-146.
  76. Magliani W, Conti S, De Bernardis F, *et al.* Therapeutic potential of anti-idiotypic single chain antibodies with yeast killer toxin activity. Nat Biotechnol 1997; 15: 155-158.
  77. Beninati C, Oggioni MR, Boccanera M, *et al.* Therapy of mucosal candidiasis by expression of an anti-idiotypic in human commensal bacteria. Nat Biotechnol 2000; 18: 1060-1064.
  78. Bromuro C, Torosantucci A, Chiani P, *et al.* Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a *Candida albicans* vaccine. Infect Immun 2002; 70: 5462-5470.
  79. Aliouat EM, Cailliez JC, Séguy N, *et al.* Inhibitory effect of a yeast killer toxin to the *in vitro* *Pneumocystis carinii* attachment. Serodiagn Immunother Infect Dis 1993; 5: 102-106.
  80. Séguy N, Polonelli L, Dei-Cas E, Cailliez JC. Perspectives in the control of *Pneumocystis carinii* infections by using *Pichia anomala* killer toxin-like anti-idiotypic antibodies. FEMS Immunol Med Microbiol 1999; 22: 145-149.
  81. Cenci E, Mencacci A, Spreca A, *et al.* Killer anti-idiotypes protect from early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect Immun 2002; 70: 2375-2382.
  82. Conti S, Fanti F, Magliani W, *et al.* Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies. J Infect Dis 1998; 177: 807-811.
  83. Conti S, Magliani W, Arseni S, *et al.* In vitro activity of monoclonal and recombinant yeast killer toxin-like antibodies against antibiotic resistant gram-positive cocci. Mol Med 2000; 6: 613-619.
  84. Cassone A., De Bernardis F, Conti S, Polonelli L. Antibodies, killer toxins, and antifungal immunoprotection: a lesson from nature? Immunol Today 1997; 18: 164-169.